A multicenter Spanish study of atropine 0.01% in childhood myopia progression

Pérez-Flores, I.; Macías-Murelaga, B.; Barrio-Barrio, Jesús

doi:10.1038/s41598-021-00923-1

Cited by 15 publications

(23 citation statements)

References 46 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the Low-Concentration Atropine for Myopia Progression (LAMP) study, 0.01% atropine, despite its inferior efficacy compared with 0.025% and 0.05% atropine, still showed a 27% and 27.7% reduction in myopia progression 1 and 2 years after treatment, respectively 20,21 . Other studies have also demonstrated the efficacy of 0.01% atropine in treating childhood myopia [22][23][24][25][26][27][28][29][30][31][32][33][34] . However, limited information is available concerning who would benefit most…”

mentioning

confidence: 99%

Characteristics of responders to atropine 0.01% as treatment in Asian myopic children

Lee

Hsieh

Chen

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Recently, low-concentration atropine (0.01%) has gained increased attention in controlling myopia progression with satisfying effects and minimal side effects. However, studies concerning responders to 0.01% atropine are limited. This retrospective observational cohort study aimed to determine the responder characteristics of 0.01% atropine in Asian children. One hundred forty children (aged between 3 and 15 years) receiving 0.01% atropine were analyzed for the factors influencing annual spherical equivalent changes (SE). The mean age was 9.13 (2.6) years, the mean baseline SE was − 1.56 (1.52) diopters (D), and the mean annual SE change was − 0.52 (0.49) D. A 58.63% responder rate (146/249) of myopic control was achieved with 0.01% atropine in our entire cohort under the criteria of less than 0.5 D of myopic progression annually. The subjects were stratified into 4 subgroups based on a cut-off point of baseline SE of − 1.5 D and baseline age of 9 years. The responder rate differed significantly with the highest being the youngest with the lowest myopia subgroups. Our results demonstrated that children with myopia better than − 1.5 D and younger than 9 years had the highest potential to achieve successful myopic control under 0.01% atropine therapy.

show abstract

mentioning

confidence: 99%

Characteristics of responders to atropine 0.01% as treatment in Asian myopic children

Lee

Hsieh

Chen

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Perez-Flores et al conducted a multicenter study that also proved 0.01% atropine eye drops have efficacy and safety in a Spanish cohort [ 18 ]. Mean SE progression before treatment was −1.01 (SD 0.38) D a year versus −0.44 (SD 0.41) D a year while using 0.01% atropine eye drops ( p < 0.001).…”

Section: Resultsmentioning

confidence: 99%

“…In a Spanish cohort a mean increase of 0.74 mm in pupil diameter (PD) was observed when using 0.01% atropine eye drops [ 18 ]. Cyphers and colleagues evaluated symptoms and ocular findings associated with the use of 0.01% atropine eye drops for one week in young adults aged 21–30 years [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

The Effectiveness and Tolerability of Atropine Eye Drops for Myopia Control in Non-Asian Regions

Simonaviciute

Grzybowski

Lança

et al. 2023

JCM

View full text Add to dashboard Cite

Myopia is the most common ocular disorder worldwide with an increasing prevalence over the past few decades. It is a refractive error associated with excessive growth of the eyeball. Individuals with myopia, especially high myopia, are prone to develop sight-threatening complications. Currently, atropine is the only drug that is used to slow myopia progression in clinical practice. However, there are still areas of uncertainty such as treatment strategy, optimal concentration when considering risk–benefit ratio and active treatment period. Since the prevalence of myopia is much higher in Asian countries, most of the research on myopia control has been conducted in Asia. Data on the efficacy and tolerability to atropine eye drops in the non-Asian population remains limited. In this review, we summarize the results of published clinical trials on the effectiveness and tolerability of atropine eye drops for myopia control in non-Asian regions. The efficacy was evaluated by the mean change in spherical equivalent (SE) or axial length (AL). The tolerability of atropine eye drops was analyzed based on patients complains and adverse events. The results of this review suggest that 0.01% atropine eye drops are effective in non-Asian regions achieving less side effects compared to 0.5% concentration.

show abstract

“…Several studies corroborate the use of cycloplegics in treating childhood myopia through the significant increase in choroidal thickness; however, treatment with cyclopentolate is not recommended due to other cycloplegics with a longer duration of effect. [47][48][49][50][51] Anterior Segment Analgesics…”

Section: Treatment Of Childhood Myopiamentioning

confidence: 99%

Ocular Cyclopentolate: A Mini Review Concerning Its Benefits and Risks

Contreras-Salinas¹,

Orozco-Ceja²,

Romero-López³

et al. 2022

OPTH

View full text Add to dashboard Cite

Cycloplegic and mydriatic agents are essential in ophthalmological clinical practice since they provide the means for diagnosing and treating certain eye conditions. In addition, cyclopentolate has proven to possess certain benefits compared to other available cycloplegics and mydriatics. Still, the incidence of some adverse drug reactions related to this drug, especially in susceptible patients, has created interest in reviewing the literature about the benefits and risks of using cyclopentolate. A literature search was conducted in Medline/PubMed and Google Scholar, focusing on identifying cyclopentolate’s benefits and risks; the most important benefit was its usefulness for evaluating refractive errors, especially for hyperopic children, pseudomyopia, anterior uveitis, treatment of childhood myopia, idiopathic vision loss, and during examinations before refractive surgery, with particular advantages compared to other cycloplegics. While the risks were divided into local adverse drug reactions such as burning sensation, photophobia, hyperemia, punctate keratitis, synechiae, and blurred vision, which are relatively frequent but mild and temporary; and systemic adverse drug reactions such as language problems, visual or tactile hallucinations and ataxia, but unlike ocular, systemic adverse drug reactions are rare and occur mainly in patients with risk factors. In addition, six cases of abuse were found. The treatment with cyclopentolate is effective and safe in most cases; nevertheless, special care must be taken due to the potential severe ADRs that may occur, especially in susceptible patients like children, geriatrics, patients with neurological disorders or Down’s syndrome, patients with a low blood level of pseudocholinesterase, users of substances with CNS effects, and patients with a history of drug addiction. The recommendations are avoiding the use of 2% cyclopentolate and instead employing solutions with lower concentrations, preferably with another mydriatic such as phenylephrine. Likewise, the occlusion of the nasolacrimal duct after instillation limits the drug’s absorption, reducing the risk of systemic adverse events.

show abstract

A multicenter Spanish study of atropine 0.01% in childhood myopia progression

Cited by 15 publications

References 46 publications

Characteristics of responders to atropine 0.01% as treatment in Asian myopic children

Characteristics of responders to atropine 0.01% as treatment in Asian myopic children

The Effectiveness and Tolerability of Atropine Eye Drops for Myopia Control in Non-Asian Regions

Ocular Cyclopentolate: A Mini Review Concerning Its Benefits and Risks

Contact Info

Product

Resources

About